(94.2%) and 10/14 IMF (71.4%) and EEC formation was seen in 42/73 ET (57.5%), 48/51 PV (94.1%) and 9/13 IMF (69.2%).
Analysis of the three biomarkers was feasible in 127 patients (68 ET, 47 PV and 12 IMF) who were classified into three groups according to the results. A first group comprised 63/127 patients (49.6%) who showed simultaneous positivity of all markers, a second group in which all markers were concomitantly negative consisted of 21/127 patients (16.5%), and, finally, a third group was defined by the coexistence of positive and negative results in 43/127 (33.9%) patients. The distribution of the three groups according to diagnosis (Table 1) showed that in the majority of PV patients (83%), all markers were simultaneously positive, 15% had both positive and negative markers and only one patient was negative for the three biomarkers. When considering IMF, 50% of the patients showed concurrent positive markers, whereas only in one case all markers were negative and in the remaining five cases (42%) positive and negative markers were observed. In ET patients, the distribution pattern of markers was as follows: coinciding positivity of all markers was seen in 27% patients, simultaneous negativity in 28% and in 45% of patients the concomitant presence of positive and negative cases was observed. The comparison of group distribution between PV and ET showed a significant difference (Po0.001), whereas no significant differences were seen when comparing IMF with PV or ET.
Several authors have studied the JAK2 V617F mutation, EEC and PRV-1 overexpression in Ph-negative CMD patients. Baxter et al. 1 showed a correlation between EEC and the presence of JAK2 V617F. More recently, two studies have demonstrated a strong correlation between JAK2 V617F mutation and PRV-1 overexpression in PV, ET and IMF, suggesting an allele dosedependent effect of JAK2 V617F on granulocyte PRV-1 expression. 6, 8 Goerttler et al. 7 have studied the clustering of JAK2 V617F mutation with EEC and PRV-1 overexpression, suggesting that the simultaneous coexistence of the three of them defines a similar group of patients from the biological point of view, irrespective of clinical categories.
Our results confirm the strong correlation of these three biomarkers in PV and to a lesser extent in IMF. ET patients, however, showed a heterogeneous pattern of biomarker expression suggesting that ET is a biologically heterogeneous disease. In this regard, additional studies are required in order to identify sub-populations of ET patients defined by biomarker characteristics and their possible correlation with different clinical behaviors. Chromosomal analysis by fluorescence in situ hybridisation (FISH) 1 and functional analysis of the ATM-p53 pathway 2 each provide powerful prognostic information in chronic lymphocytic leukaemia (CLL), but the relationship between these prognostic factors has not previously been investigated. This is a matter of considerable interest as p53 and ATM (a positive regulator of p53) are encoded at loci (17p13 and 11q23, respectively) that frequently undergo mono-allelic deletion, CMDs, chronic myeloproliferative disorders; ET, essential thrombocythemia; PV, polycythemia vera; IMF, idiopathic myelofibrosis.
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whereas an extra copy of the gene encoding MDM2 (a negative regulator of p53) is present in cases with trisomy 12. 3 To investigate the extent of correlation between these two biological variables, 191 cases of CLL were subjected to chromosomal and p53 functional analysis.
Chromosomal abnormalities were detected by FISH using probes corresponding to D13S25 (13q14), D12Z3 (centromeric region of chromosome 12), p53 (17p13) and either ATM or YAC 755b11 (11q23). For cases analysed at the Royal Marsden Hospital (n ¼ 47), a cutoff of 5% was established for deletions of D13S25, p53 and ATM, 2% for trisomy 12 and 10% for YAC 755b11. For cases analysed in Liverpool (n ¼ 144), a cutoff of 5% was used for each probe. The overall proportion of patients found to have del(17)(p13), del(11)(q23), trisomy 12 and del(13)(q14) was 15, 19, 16 and 51%, respectively. Thirty-seven patients (19%) had more than one of these FISH defects, whereas 47 cases (25%) had none. To simply analysis, each patient was assigned a single karyotype in accordance with the hierarchical prognostic model proposed by Dohner et al.,
1 in which del(17)(p13), del(11)(q23), trisomy 12 and del(13)(q14) have a descending order of importance. The overall frequency of each hierarchical karyotype obtained in this way (denoted as 17pÀ, 11qÀ, þ 12, 13qÀ and normal) was 15, 17, 13, 31 and 25%, respectively.
To determine p53 functional status, CLL cells were exposed to IR, cultured overnight and examined for levels of p53 and p21 using flow cytometry. 4 This method has been shown to produce results very similar to those obtained by Western blotting but has the advantage of being rapid, objective and quantitative. In accordance with our previous report, p53 dysfunction was defined as failure of IR to upregulate p21 by more than 25% above baseline, taking the mean fluorescence intensity (MFI) value as a measurement of p21 levels. 4 Patients with p53 dysfunction were further separated into two groups according to whether or not basal levels of p53 were increased, using a cutoff MFI value of 15 units. 4 Impaired p21 upregulation associated with constitutive p53 overexpression ('type A' p53 dysfunction) has previously been linked with TP53 mutation, whereas impaired p21 upregulation with no such p53 overexpression ('type B' p53 dysfunction) has been linked to mutation of ATM, a kinase that phosphorylates and activates p53 in response to double-strand DNA breaks.
5 Figure 1 shows how cases were classified using these criteria. The overall frequency of type A and type B p53 dysfunction was 6 and 38%, respectively. Conversely, p53 dysfunction was not detected in 56% of cases. Table 1 shows the relationship between p53 functional status and hierarchical karyotype. The frequency of p53 dysfunction among cases classified as 17pÀ, 11qÀ, þ 12, 13qÀ and karyotypically normal was 75, 59, 20, 35 and 40%, respectively. p53 dysfunction was significantly more common among patients with del(17)(p13) as compared with the rest (odds ratio 4.76, 95% CI 1.91-11.85, P ¼ 0.0003). When patients with del(17)(p13) were excluded from analysis, a strong association was also observed between p53 dysfunction and del(11)(q23) (odds ratio 2.89, 95% CI 1.31-6.39, P ¼ 0.0072). In contrast, among patients with neither del(17)(p13) nor del(11)(q23), trisomy 12 was associated with a lower-than-expected frequency of p53 dysfunction (odds ratio 0.271, 95% CI 0.88-0.835, P ¼ 0.0166). With the exception of only three cases, the type A p53 defect was confined to patients with del(17)(p13). However, among cases with del(17)(p13), the type B defect occurred more frequently than the type A defect (13 versus eight cases).
Examining the relationship between karyotype and p53 functional status the other way round, cases classified as 17pÀ, 11qÀ, 13qÀ and karyotypically normal were equally represented among the 84 patients with p53 dysfunction. In contrast, only 5% of the p53 dysfunctional patients were classified as þ 12. Among the 73 patients with type B p53 dysfunction, the findings were broadly similar, although 17pÀ patients were less well represented. Among the 11 patients with type A p53 dysfunction, the most frequent hierarchical karyotype was 17pÀ (eight cases), whereas none of these cases had a normal karyotype or del(13)(q14) as the sole abnormality. Among the 107 cases with no p53 dysfunction, the frequency of each hierarchical karyotype varied widely, favourable ones occurring more frequently than unfavourable ones (13qÀ in 36% of cases, normal karyotype in 26%, þ 12 in 19%, 11qÀ in Separation of CLL cases into p53 functional groups. Each data point on the dot plot represents an individual case. Levels of p53 in untreated cells are shown on the X-axis, and the proportional increase in p21 produced by IR on the Y-axis. Predefined cutoff values of 25% for IR-induced p21 upregulation and 15 units for baseline p53 were used to separate cases into those with type A p53 dysfunction, those with type B p53 dysfunction, and those with no p53 dysfunction. 4 
Table 1
Relationship Letters to the Editor 12%, 17pÀ in 6%). Poor-risk karyotype (17pÀ or 11qÀ) was a feature of 82% of patients with type A p53 dysfunction, 42% of patients with type B p53 dysfunction, and only 19% of patients with no p53 dysfunction. Conversely, good-risk karyotype (13qÀ or no FISH defects) was a feature of 63% of the patients with no p53 dysfunction, 42% of the patients with type B p53 dysfunction, and none of the patients with type A p53 dysfunction.
Since deletions of 17p13 and 11q23 were detected in only a proportion of cells in a given case, it was of interest to examine whether there was any correlation between p53 dysfunction and deletion frequency. Among patients with del(17)(p13), a negative linear correlation (r ¼ À0.688, Po0.001) was observed between the amount of IR-induced p21 upregulation and the proportion of cells harbouring a TP53 deletion (Figure 2a) . Consequently, p53 dysfunction (less than 25% IR-induced p21 upregulation) was present in all 17 cases with greater than 50% TP53 deletion, compared with only four of the 11 patients with less than 50% deletion (P ¼ 0.0003). Baseline p53 levels were also more frequently elevated in cases with greater than 50% deletion (odds ratio 8.89, 95% CI 0.922-85.65, P ¼ 0.0491; Figure 2b ). In contrast to 17pÀ cases, no correlation was observed in 11qÀ cases between and deletion frequency and p53 dysfunction.
In some patients, FISH analysis for 11q23 deletion was performed using the YAC probe 755b11, whereas in other cases an ATM probe was used. The two probes bind to closely linked but distinct, nonoverlapping loci. A comparison of 11qÀ cases detected with the ATM probe (11qÀ ATM ) versus those detected with the YAC probe (11qÀ YAC ) showed no difference in the frequency of p53 dysfunction (10 of the 17 11qÀ ATM patients versus nine of the 15 11qÀ YAC patients) or in the proportion of cells with an 11q23 deletion.
The overall frequency of chromosomal abnormalities and p53 dysfunction in the present study is broadly consistent with previous reports. 2, 3, 5, 6 However, the proportion of cases with type A p53 dysfunction was much lower than previously reported and the proportion with the type B defect correspondingly higher. 2, 5, 6 This discrepancy is unlikely to be due to differences in methodology since the flow cytometric method for detecting p53 dysfunction has been validated against the Western blotting method and gives comparable results. 4 A more likely explanation for the discrepancy is that the present study involved predominantly newly diagnosed or previously untreated patients, whereas previous studies have included many samples from heavily pre-treated patients.
It is interesting that not all patients with del(17)(p13) had demonstrable p53 dysfunction. It is possible that p53 dysfunction was not detected in some of these cases because the proportion of cells with a p53 defect was below the limit of detection. This idea is supported by the correlation observed between p53 dysfunction and the proportion of cells with a TP53 deletion (Figures 2a and b) . Alternatively, it is possible that in some cases with a TP53 deletion the remaining allele was not inactivated. This idea is supported by a previous report in which only 5 out of 11 cases of CLL with a TP53 deletion had a demonstrable mutation of the remaining allele. 7 Another point of interest among 17pÀ cases is that the type B defect occurred almost twice as frequently as the type A defect. This suggests that TP53 deletion can be accompanied by inactivation of the remaining TP53 allele through mechanisms that do not necessarily result in p53 protein stabilisation and consequent over-expression.
The observed association in the present study between 11qÀ and p53 dysfunction suggests that deletion of ATM is accompanied by inactivation of the remaining allele in a high proportion of cases. Interestingly, the frequency of p53 dysfunction observed among 11qÀ cases (about 60%) is much higher than the frequency of ATM mutations previously reported in such cases. 8 This suggests that p53 functional analysis may detect forms of ATM inactivation that evade detection by structural analysis of the ATM gene. Despite the association between del(11)(q23) and p53 dysfunction, about 40% of patients with 11qÀ had no evidence of p53 dysfunction. This could be because the remaining ATM allele was not inactivated in these cases, or because it was inactivated in a way that evaded detection.
The negative association found between p53 dysfunction and 12 þ is difficult to explain but is nevertheless in keeping with the notion that trisomy 12 may not necessarily have adverse prognostic significance in CLL. 1 The occurrence of p53 dysfunction in patients with neither del(17)(p13) nor del(11)(q23) has a number of possible explanations, including inactivation of ATM or p53 by bi-allelic mutation, dominant-negative mono-allelic mutation, epigenetic gene silencing, or post-translational modification. In addition, it is possible that in some cases p53 dysfunction might result from deregulation of other components of the ATM-p53 pathway.
In conclusion, the present study has confirmed the expected association between p53 dysfunction and deletion of TP53 or ATM but has also revealed a surprising degree of discordance. This suggests that chromosomal analysis and p53 functional analysis may provide complementary prognostic information in The discovery in 1994 of 263 bodies buried in a church crypt in Vác, Hungary (Figure 1a and b) has led to some intense investigation and findings of Mycobacterium tuberculosis DNA. 1 These bodies were all interred in coffins which, unusually, yielded many skeletal remains of infants in a nearprefect state of preservation. One such body, of an infant, was found to have numerous bony lesions present throughout the skeleton. They appear punched out lytic lesions, with no apparent reactive changes at the edges. Under normal burial conditions, such fragile bones would have been so damaged that the lesions may well have escaped notice, been regarded as post-mortem damage, or even been destroyed completely.
While many of the people interred in the crypt had their names and ages of birth and death painted on their coffins, in the case of this infant nothing was written on the coffin. However, the likely date of the burial is approximately 1750-1770, as coffins were lowered into the crypt in sequential order. The approximate age of this child based on measurements of the long bones is 18-30 months, but if based on tooth eruption it would be 18 months. We thus put the age at between 1.5-2.5 years. The ribs contain lesions showing evidence of pure osteolytic effects with no evidence of any attempt at healing (Figure 2 ). The lesions appear to commence in the marrow and subsequently breach the surface. However, as they breach the surface these lesions can cause a reaction in the periosteum. This can be seen in the new bone formation noted in Figure 2 . Figures 3 (petrous temporal bone) and 4 (pelvic bone) show the bone with typical destructive and multiple lytic lesions, varying in size between 3 and 8 mm. In fact, all bones X-rayed showed such changes. One rib (Figure 5a and b) was tested for the presence of M. tuberculosis DNA as part of our general investigation of this population for tuberculosis. Using primers specific for the M. tuberculosis complex based on a 123 bp target region of the repetitive insertion sequence IS6110, nested PCR was performed and yielded a 92 bp product. Interestingly, while scrapings from the visceral surface of the rib were positive, bone from the lesion margin was not.
In a differential diagnosis of these findings, we have excluded the possibility of the lesions being due to miliary tuberculosis because of the X-ray appearance, and also such diseases as chronic granulomatous disease (CGD). The latter represents a group of genetic disorders in which impaired intracellular microbial killing by phagocytes leads to granuloma formation caused by recurrent bacterial and fungal infections. In CGD, bony lesions are common but while these are destructive they should, as do nearly all such lesions due to bacteria, show some evidence of attempted healing. 2 Langerhans' cell histiocytosis (LCH), also referred to as Histiocytosis-X, is a spectrum of disorders characterised by overproliferation and accumulation as lesions of 'histiocytes' -tissue-resident macrophages and dendritic cells, which are derived from bone-marrow stem cells in the various tissues and organs of the body. 3 The lesions can include Langerhans cells, the distinctive epidermal antigen-presenting dendritic cells, as well as other white blood cells such as monocytes or eosinophils. The second form of histiocytosis most often encountered in children is haemophagocytic lymphohistiocytosis (HLH), a disease of mononuclear phagocytes.
The aetiology and pathogenesis of histiocytosis are still unknown. Early studies suggested that it was a reactive disease caused by abnormal immune regulation. A contrary view is that the histiocytes in this condition are of a clonal type, and thus this is neoplastic rather than a reactive disorder. It is now thought to be more probable that LCH is indeed a neoplasm, with a spectrum of clinical manifestations varying from benign and spontaneously resolving, to highly malignant and fatal. 4 The condition is rare with an incidence for LCH of around 1:200 000 children. 5 The peak incidence is in children aged 1-3 years,
